Back to Report Store Home

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

  • Published: Mar-2018
  • Report Code: GBIHC472MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 12

2.1 Therapy Area Overview 12

2.1.1 Rheumatoid Arthritis 12

2.1.2 Psoriasis 13

2.1.3 Inflammatory Bowel Disease 14

2.1.4 Graft Versus Host Disease and Transplant Rejection 15

2.2 Symptoms 16

2.3 Diagnosis 19

2.3.1 Rheumatoid Arthritis 19

2.3.2 Psoriasis 19

2.3.3 Inflammatory Bowel Disease 19

2.3.4 Graft Versus Host Disease and Transplant Rejection 20

2.4 Etiology and Pathophysiology 20

2.4.1 Rheumatoid Arthritis 23

2.4.2 Psoriasis 24

2.4.3 Inflammatory Bowel Disease 25

2.4.4 Graft Versus Host Disease and Transplant Rejection 26

2.5 Epidemiology 27

2.5.1 Rheumatoid Arthritis 28

2.5.2 Psoriasis 28

2.5.3 Inflammatory Bowel Disease 29

2.5.4 Graft Versus Host Disease and Transplant Rejection 31

2.6 Co-morbidities and Complications 31

2.7 Treatment 32

2.7.1 Rheumatoid Arthritis 33

2.7.2 Psoriasis 35

2.7.3 Inflammatory Bowel Disease 36

2.7.4 Graft-Versus-Host Disease and Transplant Rejection 37

3 Key Marketed Products 40

3.1 Overview 40

3.2 Humira (adalimumab) – AbbVie 41

3.3 Enbrel (etanercept) - Amgen 43

3.4 Remicade (infliximab) – Johnson & Johnson 45

3.5 Rituxan (rituximab) – Roche 48

3.6 Stelara (ustekinumab) – Johnson & Johnson 50

3.7 Simponi (golimumab) – Johnson & Johnson 52

3.8 Orencia (abatacept) – Bristol-Myers Squibb 54

3.9 Tysabri (natalizumab) – Biogen 56

3.10 Actemra (tocilizumab) – Roche 58

3.11 Prograf (tacrolimus) – Astellas 60

3.12 Cimzia (certolizumab) – UCB 62

3.13 Entyvio (vedolizumab) - Takeda 64

3.14 Cosentyx (secukinumab) - Novartis 65

3.15 Otezla (apremilast) - Celgene 67

3.16 Xeljanz (tofacitinib) – Pfizer 68

3.17 Taltz (ixekizumab) – Eli Lilly 70

4 Pipeline Landscape Assessment 72

4.1 Overview 72

4.2 Pipeline Development Landscape 72

4.3 Molecular Targets in the Pipeline 76

4.4 Clinical Trials Landscape 79

4.4.1 Clinical Trial Failure Rates 80

4.4.2 Clinical Trial Duration 82

4.4.3 Clinical Trial Size 86

4.4.4 Cumulative Clinical Program Size 90

4.5 Assessment of Key Late-Stage Pipeline Products 93

4.5.1 Filgotinib – Galapagos and Gilead Sciences 93

4.5.2 AR-101 – Aimmune Therapeutics 94

4.5.3 Upadacitinib tartrate – AbbVie 95

4.5.4 Lanadelumab – Shire 97

4.5.5 Ozanimod hydrochloride – Celgene 98

4.5.6 Risankizumab – AbbVie 99

4.6 Conclusion 101

5 Multi-scenario Market Forecast to 2023 102

5.1 Overall Market Size 102

5.2 Generic Penetration 104

5.3 Revenue Forecast by Molecular Target 105

5.3.1 Cytokines and Cytokine Receptors 106

5.3.2 Intracellular Signal Transducers 107

5.3.3 Cell Surface Antigens 108

5.3.4 Intercellular Interaction and Adhesion Molecules 109

6 Company Analysis and Positioning 111

6.1 Revenue and Market Share Analysis by Company 113

6.1.1 AbbVie 118

6.1.2 Johnson & Johnson 119

6.1.3 Novartis 120

6.1.4 Pfizer 122

6.1.5 Roche 123

6.1.6 Amgen 124

6.1.7 Celgene 125

6.1.8 Eli Lilly 126

6.2 Company Landscape 127

6.3 Marketed and Pipeline Portfolio Analysis 128

7 Strategic Consolidations 131

7.1 Licensing Deals 131

7.1.1 Deals by Region, Year and Value 131

7.1.2 Deals by Indication 132

7.1.3 Deals by Stage of Development 133

7.1.4 Deals by Molecule Type, Molecular Target and Value 134

7.1.5 Table for Licensing Deals with Disclosed Values 135

7.2 Co-development Deals 138

7.2.1 Deals by Region, Year and Value 138

7.2.2 Deals by Indication 139

7.2.3 Deals by Stage of Development 140

7.2.4 Deals by Molecule Type, Molecular Target and Value 141

7.2.5 Table for Co-development Deals with Disclosed Values 142

8 Appendix 144

8.1 References 144

8.2 Figures of All Clinical Stage Pipeline Products 157

8.3 Abbreviations 177

8.4 Disease List 178

8.5 Methodology 178

8.5.1 Coverage 179

8.5.2 Secondary Research 179

8.5.3 Market Size and Revenue Forecasts 179

8.5.4 Pipeline Analysis 180

8.5.5 Competitive Landscape 180

8.6 Contact Us 180

8.7 Disclaimer 181

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards